% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • retired_4now retired_4now Oct 7, 2013 2:46 PM Flag

    Celldex Therapeutics, Inc. - Product Pipeline Review - 2013

    Global Market Direct’s pharmaceuticals report, “Celldex Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on the Celldex Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

    This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Celldex Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Celldex Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


    - Celldex Therapeutics, Inc. - Brief Celldex Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
    - Review of current pipeline of Celldex Therapeutics, Inc. human therapeutic division.
    - Overview of pipeline therapeutics across various therapy areas.
    - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
    - Product profiles for late stage and clinical stage products of Celldex Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
    - Recent updates of the Celldex Therapeutics, Inc.’s pipeline in the last quarter.
    - Key discontinued and dormant projects.
    - Latest news and deals relating to the products.

    Reasons to buy

    - Evaluate Celldex Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
    - Assess the growth potential of Celldex Therapeutics, Inc. in its therapy areas of focus.
    - Identify new drug targets and therapeutic classes in the Celldex Therapeutics, Inc.’s R&D portfolio and develop key strategi

    Sentiment: Buy

4.04+0.24(+6.32%)Sep 30 4:00 PMEDT